Sixteen Years of HPV Vaccination in Mexico: Report of the Coverage, Procurement, and Program Performance (2008–2023)

Rodrigo Romero-Feregrino, Raúl Romero-Cabello, Raúl Romero-Feregrino (), Paulina Vilchis-Mora, Berenice Muñoz-Cordero and Mario Alfredo Rodríguez-León
Additional contact information
Rodrigo Romero-Feregrino: Asociación Mexicana de Vacunología, Instituto Para el Desarrollo Integral de la Salud (IDISA), Instituto Mexicano del Seguro Social (IMSS), CONCAMIN, Saint Luke School of Medicine, Academia Mexicana de Pediatria, Av. Cuauhtémoc 271, Interior 101, Colonia Roma, Cuauhtémoc, Mexico City ZC 06700, Mexico
Raúl Romero-Cabello: Asociación Mexicana de Vacunología, Instituto Para el Desarrollo Integral de la Salud (IDISA), Hospital General de México, Department of Microbiology and Parasitology, Universidad Nacional Autónoma de México (UNAM), Saint Luke School of Medicine, Academia Mexicana de Pediatria, Av. Cuauhtémoc 271, Interior 101, Colonia Roma, Cuauhtémoc, Mexico City ZC 06700, Mexico
Raúl Romero-Feregrino: Asociación Mexicana de Vacunología, Instituto Para el Desarrollo Integral de la Salud (IDISA), UMAE Hospital de Pediatría “Dr. Silvestre Frenk Freund”, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Saint Luke School of Medicine, Academia Mexicana de Pediatria, Av. Cuauhtémoc 271, Interior 101, Colonia Roma, Cuauhtémoc, Mexico City ZC 06700, Mexico
Paulina Vilchis-Mora: Saint Luke School of Medicine, Sierra Mojada 415, Lomas de Chapultepec III Secc, Miguel Hidalgo, Mexico City ZC 11000, Mexico
Berenice Muñoz-Cordero: Asociación Mexicana de Vacunología, Instituto Para el Desarrollo Integral de la Salud (IDISA), Pediatrics Department/Hospital General de Cuajimalpa IMSS-Bienestar, Av. Cuauhtémoc 271, Interior 101, Colonia Roma, Cuauhtémoc, Mexico City ZC 06700, Mexico
Mario Alfredo Rodríguez-León: Asociación Mexicana de Vacunología, Instituto Para el Desarrollo Integral de la Salud (IDISA), Universidad Nacional Autónoma de México (UNAM), Av. Cuauhtémoc 271, Interior 101, Colonia Roma, Cuauhtémoc, Mexico City ZC 06700, Mexico

IJERPH, 2025, vol. 22, issue 7, 1-15

Abstract: Introduction: In 2008, Mexico initiated its national HPV vaccination program targeting adolescent girls. This study aims to evaluate the current status of the program, analyzing trends in vaccine acquisition, administration, and coverage over a 16-year period. Materials and Methods: A retrospective longitudinal study was conducted using secondary data from 2008 to 2023. Official records from three major public health institutions—IMSS, ISSSTE, and SSA—were reviewed to assess HPV vaccine procurement and administration. Results: Significant fluctuations were identified in the number of doses acquired, administered, and the corresponding coverage rates. A marked decline was observed between 2019 and 2021, followed by a sharp increase in 2022 and 2023. Over the entire period, an estimated 6.8 million doses were not administered to the intended target population. Furthermore, 2.6 million doses were administered in excess of the number officially acquired, indicating possible discrepancies in data reporting or vaccine inventory management. Discussion: The findings revealed substantial inconsistencies in vaccine procurement, administration, and coverage across institutions. While IMSS and ISSSTE consistently reported coverage below the theoretical target, SSA occasionally exceeded expectations, potentially compensating for deficits elsewhere. Nevertheless, national coverage remained inadequate in several years, with notable disparities between institutions. These gaps highlight systemic weaknesses in program coordination, planning, and data transparency, contributing to millions of unvaccinated individuals. Conclusions: This study offers a comprehensive analysis of Mexico’s HPV vaccination program, uncovering critical irregularities in its implementation. Challenges include inaccurate target population estimation, inconsistencies between vaccine acquisition and administration, and limited data reliability. Despite some progress in recent years, particularly in the post-pandemic years, the program requires urgent restructuring. This includes implementing a national catch-up strategy, expanding vaccine eligibility, and strengthening surveillance systems to ensure equitable and effective coverage toward the elimination of cervical cancer.

Keywords: vaccination; human papilloma virus; coverage; Mexico; public health; human papillomavirus (HPV) vaccination; immunization program evaluation; vaccine coverage assessment; HPV vaccine; public health surveillance; cervical cancer prevention strategies; health information systems and data quality; vaccination program performance in Mexico; papillomavirus vaccines; immunization programs; vaccination coverage; health services accessibility; public health surveillance; uterine cervical neoplasms/prevention and control; health information systems; Mexico/epidemiology (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/22/7/1028/pdf (application/pdf)
https://www.mdpi.com/1660-4601/22/7/1028/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:22:y:2025:i:7:p:1028-:d:1689495

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().